PresseBox
Pressemitteilung BoxID: 529067 (4SC AG)
  • 4SC AG
  • Fraunhoferstr. 22
  • 82152 Planegg-Martinsried
  • http://www.4sc.de
  • Ansprechpartner
  • Jochen Orlowski
  • +49 (89) 700763-66

4SC AG further strengthens Supervisory Board with experienced managers from the pharmaceutical industry

(PresseBox) (Planegg-Martinsried, ) 4SC AG (Frankfurt, Prime Standard: VSC), a discovery and development company of targeted small molecule drugs for autoimmune and cancer diseases, today announced the appointment of Dr Irina Antonijevic and Mr Klaus Kühn to the company's Supervisory Board.

In a by-election at today's Annual General Meeting of 4SC AG, Dr Antonijevic and Mr Kühn were elected to the Supervisory Board for the remaining term of Dr Jörg Neermann and Mr Günter Frankenne, who have stepped down from the Supervisory Board. The terms of office will run until the end of the Annual General Meeting that resolves on formally approving the actions of the Supervisory Board for financial year 2012.

Dr Antonijevic, Director Clinical Research at US pharmaceutical company Sanofi, has many years of international experience in clinical drug development and extensive expertise gained in executive positions both in the pharmaceutical industry and in medical research in a university environment.

Klaus Kühn, former Chief Financial Officer of Bayer AG (2002 to 2010), has more than 30 years of experience in executive positions primarily in the chemical and pharmaceutical industry with a focus on finance and accounting.

The shareholders of 4SC AG also approved all of the resolutions proposed to the Annual General Meeting by the Management Board and the Supervisory Board with the required majority, including the following items:

- Resolution on the approval of the remuneration system for members of the Management Board;

- Approval of a control and profit transfer agreement between 4SC AG and 4SC Discovery GmbH;

- Resolution on the creation of new Authorised Capital, adjusted to the share capital that was raised following the capital increase in June 2012;

- Resolution on a new authorisation of the Management Board to issue convertible bonds, bonds with warrants, profit participation rights and/or income debentures and create corresponding Conditional Capital.

A total of 78.3% of the voting capital was represented at the 2012 Annual General Meeting of 4SC AG.

This document may contain projections or estimates relating to plans and objectives relating to our future operations, products, or services; future financial results; or assumptions underlying or relating to any such statements; each of which constitutes a forward-looking statement subject to risks and uncertainties, many of which are beyond our control. Actual results could differ materially, depending on a number of factors.

4SC AG

The Group managed by 4SC AG (ISIN DE0005753818) discovers and develops targeted, small-molecule drugs for treating diseases with high unmet medical needs in various autoimmune and cancer indications. These drugs are intended to provide innovative treatment options that are more tolerable and efficacious than existing therapies, and provide a better quality of life. The Company's balanced pipeline comprises promising products that are in various stages of clinical development. 4SC's aim is to generate future growth and enhance its enterprise value by entering into partnerships with leading pharmaceutical companies. Founded in 1997, 4SC had 90 employees at 31 March 2012. 4SC AG has been listed on the Prime Standard of the Frankfurt Stock Exchange since December 2005.